A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (CLE)
Active Grant Awarded
- Award ID
- R41AR087258
- Recipient
-
L2 Diagnostics LLC UEI GKA7VH5LFR25
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $323,090
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 18% complete
- Place of performance
- New Haven, CT 06511, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health, through the National Institute of Arthritis and Musculoskeletal and Skin Diseases, awarded Grant R41AR087258 to L2 Diagnostics LLC, with $323,090 obligated on Sep 19, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846).
The award funds a Phase I SBIR project to establish the preclinical feasibility of L2ASOCLE, an oligonucleotide targeting the HIF1A transcript, as a first-in-class topical agent for cutaneous lupus erythematosus (CLE). The recipient will evaluate the agent's safety, delivery formulation, efficacy, and mechanistic activity in both in vitro and in vivo models of CLE. The applicant's prior studies identified HIF-1A as a critical mediator of CLE pathogenesis, which underpins the therapeutic target. The project is expected to generate proof-of-concept data to support later Phase II development.
Performance runs from the award date through an ultimate completion date of Aug 31, 2027, with place of performance in New Haven, CT 06511. The recipient's UEI is GKA7VH5LFR25. The source identifies no sub-recipients.
Description
- Abstract
- Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disorder characterized by sustained inflamma; on, immune dysregula; on, and progressive ; ssue damage. In its more persistent forms, such as discoid lupus erythematosus (DLE), IT can lead to permanent scarring and disfigurement, significantly impac; NG a PA; ENT's quality of life. CLE affects an ES; mated 3-4 individuals per 100,000 annually, with a prevalence of approximately 70 per 100,000 in the U.S. And europe. Our recent studies have iden; fied hypoxia-inducible factor 1-alpha (HIF-1Α) as a CRI; CAL mediator in the pathogenesis of CLE, sugges; NG HIF-1Α as a novel therapeu; C target. By selec; vely modula; NG HIF-1Α, L2ASOCLE targets a new elucidated key pathogenic pathway, thereby reducing skin inflamma; on and ; ssue damage. This phase I sbir project aims to establish the preclinical feasibility of L2ASOCLE, an oligonucleo; DE targe; NG the HIF1A transcript, as a first-in-class topical agent targe; NG CLE. We will evaluate its safety, delivery formula; on, efficacy and mechanis; C AC; vity in both in vitro and in vivo models of CLE. The successful comple; on of this work will provide strong proof-of-concept data to support the further development of L2ASOCLE in phase II, UL; mately advancing a targeted, disease-modifying treatment for PA; ents with CLE.
Quick answers
Who received award R41AR087258?
R41AR087258 was awarded to L2 Diagnostics LLC by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 19, 2026.
How much is award R41AR087258 worth?
$323,090 has been obligated on R41AR087258.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award